


c-Met



c-Met inhibitors

Discovery	Cat.No.	Product Name	Information	Clinical Trial
2007	S1068	Crizotinib Licensed by Pfizer	Targets IC ₅₀ (nM) c-Met 11 ALK 24	Phase 1/2
2009	S1111	Foretinib (GSK1363089)	Targets IC ₅₀ (nM) Met 0.4 KDR 0.9	Others Ron,Flt-1/3/4,Kit,PDGFRα/β,Tie-2 Phase 2
2003	S1070	PHA-665752	Targets IC ₅₀ (nM) c-Met 9	Others RTKs,STKs
2009	S1561	BMS-777607	Targets IC ₅₀ (nM) c-Met 3.9 Axl 1.1 Ron 1.8 Tyro3 4.3	Others Lck,VEGFR-2, TrkA/B Phase 1/2
2010	S2753	Tivantinib (ARQ 197)	Targets K(μM) c-Met 0.355	Others Ron Phase 3
2011	S1119	Cabozantinib (XL184, BMS-907351)	Targets IC ₅₀ (nM) c-Met 1.3 VEGFR2 0.035 Ret 4 Kit 4.6	Others Flt-1/3/4,Tie2,AXL Phase 2
2011	S2788	INCB28060	Targets IC ₅₀ (nM) c-Met 0.13	Phase 1
2009	S1112	SGX-523	Targets IC ₅₀ (nM) Met 4	Phase 1
2008	S1114	JNJ-38877605	Targets IC ₅₀ (nM) c-Met 4	Phase 1
2003	S1080	SU11274	Targets IC ₅₀ (nM) Met 10	
2009	S1094	PF-04217903	Targets IC ₅₀ (nM) c-Met 4.8	Phase 1
2009	S1124	BMS-754807	Targets IC ₅₀ (nM) Met 5.6 IGF-1R 1.8 IR 1.7	Others TrkA/B,Ron Phase 2
2010	S1361	MGCD-265	Targets IC ₅₀ (nM) c-Met 1 VEGFR1/2/3 3/4	Others Ron,Tie2 Phase 1/2
2012	S2859	Golvantinib (E7050)	Targets IC ₅₀ (nM) c-Met 14 VEGFR2 16	Phase 1/2